Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 6, 1999, Pages 606-614

  Ko, Jae Wook ^a,b   Jang, In Jin ^a,b   Shin, Jae Gook ^a,b   Nam, Sang Keon ^a,b   Shin, Sang Goo ^a,b   Flockhart, David A ^a,b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; CYTOCHROME; LANSOPRAZOLE; THEOPHYLLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PROTON PUMPS; REFERENCE VALUES; SINGLE-BLIND METHOD; THEOPHYLLINE; TIME FACTORS; VOLUNTARY WORKERS;

EID: 0032976824     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)90082-6     Document Type: Article

References (41)

1. 1. Spencer CM, Faulds D. Lansoprazole: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994;48:404-30.
2. 2. Langtry HD, Wilde MI. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997;54:473-500.
3. 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992;52:170-80.
4. 4. Cavuto NJ, Sukhova N, Hewett J, Balian JD, Woosley RL, Flockhart DA. Effect of omeprazole on theophylline clearance in poor metabolizers of omeprazole [abstract]. Clin Pharmacol Ther 1995;57:215.
5. 5. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994;55:402-11.
6. 6. Curi-Pedrosa R, Daujat M, Pichard L, Ourlin JC, Clair P, Gervot L, et al. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther 1994;269:384-92.
7. 7. Weinberger M, Hendeles L. Theophylline use: an overview. J Allergy Clin Immunol 1985;76:277-84.
8. 8. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976;21:953-6.
9. 9. Jenne JW, Nagasawa HT, Thompron R. Relationship of urinary metabolites of theophylline to serum theophylline levels. Clin Pharmacol Ther 1976;13:375-81.
10. 10. Gundert-Remy U, Hildebrandt R, Hengen N, Weber E. Non-linear elimination processes of theophylline. Eur J Clin Pharmacol 1983;24:71-8.
11. 11. Tjia JF, Colbert J, Back DJ. Theophylline metabolism in human liver microsomes: Inhibition studies. J Pharmacol Exp Ther 1996;276:912-7.
12. 12. Rasmussen BB, Mäenpää J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, et al. Selective scrotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995;39:151-9.
13. 13. Tröger U, Meyer FP. Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline: focus on biotransformation. Clin Pharmacokinet 1995;28: 287-314.
14. 14. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
15. 15. Zhang ZY, Kaminsky LS. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol 1995;50:205-11.
16. 16. Sarkar MA, Hunt C, Guzelian PS, Karnes HT. Characterization of human liver eytochromc P-450 involved in theophylline metabolism. Drug Metab Dispos 1992;20:31-7.
17. 17. Sarkar MA, Jackson BJ. Theophylline N-demethylations as probes for P4501A1 and P4501A2. Drug Metab Dispos 1994;22:827-34.
18. 18. Ha HR, Chen J, Freiburghaus AU, Follath F. Metabolism of theophylline by cDNA-expressed human cytochrome P-450. Br J Clin Pharmacol 1995;39:321-6.
19. 19. Granneman GR, Karol MD, Locke CS, Cavanaugh JH. Pharmacokinetic interaction between lansoprazole and theophylline. Ther Drug Monit 1995:17:460-4.
20. 20. Kokufu T, Ihara N, Sugioka N, Koyama H, Ohta T, Mori S, et al. Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol 1995; 48:391-5.
21. 21. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Meyer UA, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993;36:521-30.
22. 22. Pearce RE, Rodrigues D, Goldstein JA, Parkinson A. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996; 277:805-16.
23. 23. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995;57:662-9.
24. 24. Marinac JS, Balian JD, Foxworth JW, Willsie SK, Daus JC, Owen R, et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. Clin Pharmacol Ther 1996;60:138-44.
25. 25. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochromes P450(CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209.
26. 26. Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990;12: 415-6.
27. 27. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an oriental population. J Pharmacol Exp Ther 1992;262:1195-202.
28. 28. Sohn DR, Kwon JT, Kim HK, Ishizaki T. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxlyation phenotype status. Clin Pharmacol Ther 1997;61:574-82.
29. 29. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, et al. Interethnic difference in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian population. Clin Pharmacol Ther 1985;38:402-8.
30. 30. Wedlund PJ, Aslanian WS, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984;36:773-80.
31. 31. Flockhart DA. Drug interactions and the cytochrome P450 system: the role of cytochrome P450 2C19. Clin Pharmacokinet 1995;29(suppl 1):45-52.
32. 32. Karol MD, Granneman GR, Alexander K. Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography. J Chromatogr B 1995;668:182-6.
33. 33. Gleiter CH, Gundert-Remy U. Gender differences in pharmacokinetics. Eur J Drug Metab Pharmacokinet 1996;21:123-8.
34. 34. Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992;2:25-31.
35. 35. Caraco Y, Lagerstrom PO, Wood AJJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996;60:157-67.
36. 36. Taburet AM, Geneve J, Bocqueentin M, Simoneau G, Caulin C, Singlas E. Theophylline steady state pharmacokinetics are not altered by omeprazole. Eur J Clin Pharmacol 1992;42:343-5.
37. 2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther 1987;33:133-7.
38. 38. Andersson T, Bergstrand R, Cederberg C, Eriksson S, Lagerstròm PO, Skånberg I. Omeprazole treatment does not affect the metabolism of caffeine. Gastroenterology 1991;101:943-7.
39. 39. Oosterhuis B, Jonkman JHG, Andersson T, Zuiderwijk PBM. No influence of single intravenous doses of omeprazole on theophylline elimination kinetics. J Clin Pharmacol 1992;32:470-5.
40. 40. Diaz D, Fabre I, Daujat M, Aubert BS, Bories P, Michel H, et al. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 1990;99:737-47.
41. 41. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997;25:853-62.